In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
_256_384.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
Medical Device Policy is a progressive step in propelling the country towards Atmanirbharta in the heavily import dependent Medical Device Sector
The product is expected to be launched in June 2023
For Q4 ended FY23, company reported net profit of Rs. 12.56 crore as against net profit of Rs. 11.02 crore in the corresponding period last year
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Subscribe To Our Newsletter & Stay Updated
